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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects and safety of interventions targeting cognition, emotion or both as the predominant underlying mechanism of
effect to relieve breathlessness in adults suffering from advanced diseases.
B A C K G R O U N D
This protocol is partly based on suggested wording from the
Cochrane Pain, Palliative and Supportive Care Review Group
(PaPaS CRG). Some wording is used from the original review
(Bausewein 2008), which this new review will update and replace.
Description of the condition
Breathlessness or dyspnoea is defined as “subjective experience of
breathing discomfort that consists of qualitatively distinct sensa-
tions that vary in intensity” (Meek 1999). The term ’breathless-
ness’ reflects the patients’ perspective based on the daily experi-
ence whereas the medical term ’dyspnoea’ focuses more on the
clinical sign of an underlying condition (Johnson 2014). “The ex-
perience derives from interactions among multiple physiological,
psychological, social, and environmental factors, and may include
secondary physiological and behavioural responses” (Meek 1999).
Since this definition was adopted, new evidence has led to better
understanding of the mainly sensory and affective components
and that dyspnoea “must generally be distinguished from signs
that clinicians typically invoke as evidence of respiratory distress,
such as tachypn(o)ea, use of accessory muscles, and intercostal re-
tractions.” (Parshall 2012). Many patients with different condi-
tions including primary and secondary cancer, lung diseases (e.g.
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chronic obstructive pulmonary disease (COPD), pulmonary hy-
pertension, cystic fibrosis, interstitial lung disease (ILD)), chronic
heart failure (CHF) or motor neuron disease/amyotrophic lat-
eral sclerosis (MND/ALS) suffer from this distressing symptom
(Bailey 2010; Booth 2008; Breaden 2011; Lansing 2009; Solano
2006). Breathlessness is a multifactorial and complex symptom
and an experience unique to the individual (Booth 2008). It is
often expressed as air hunger, work of breathing, laboured breath-
ing, awareness of respiratory distress, and shortness of breath or
chest tightness (Barnes 2016; Parshall 2012). Breathing discom-
fort is described by such phrases as ‘could not breathe fast or deep
enough’ or ‘could not get enough air’ or ‘suffocating’ (Guz 1997).
Breathlessness is one of the most prevalent and distressing symp-
toms in advanced stages of malignant and non-malignant diseases.
Up to 95% of patients with advanced chronic pulmonary disease,
88% with advanced heart disease, and 70% with end stage cancer
experience breathlessness in their last year of life (Graham 2010;
Lansing 2009; Moens 2014; Solano 2006; Teunissen 2007). The
frequency and severity of breathlessness increase during the course
of the disease until death (Bailey 2010; Breaden 2011). It is an
extremely distressing symptom for the patient but also for the ac-
companying family and professional carers (Booth 2008).
Overall, breathlessness is still difficult to palliate.
Description of the intervention
Management of breathlessness
Appropriatemanagement to relieve breathlessness in advanced dis-
eases requires both pharmacological and non-pharmacological in-
terventions. Different systematic reviews and meta-analyses were
published in recent years and analysed the effects of pharmacologi-
cal interventions such as opioids (Barnes 2016;Mahler 2013), ben-
zodiazepines (Simon 2016), and oxygen (Ameer 2014; Cranston
2008; Sharp 2016) for breathlessness in adult patients.
However, the use of drugs to treat breathlessness is sometimes lim-
ited as they entail adverse effects and doses need to be titrated care-
fully. Therefore, non-pharmacological interventions are an impor-
tant part of the treatment of breathlessness. As mentioned above,
many systematic reviews analysed the effects of pharmacological
treatments, which is why we are focusing solely on non-pharma-
cological interventions in this review.
Non-pharmacological interventions
Many non-pharmacological interventions for the relief of breath-
lessness have been developed and evaluated in recent years. For
better clarity, we therefore categorise the interventions based on
a theoretical concept developed by Booth 2014, Chin 2016 and
Spathis 2017. This concept builds on the effect breathlessness has
on patients (Figure 1).
Figure 1. Perpetuation of breathlessness by vicious cycles (Booth 2014)
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• Respiratory: Inefficient breathing and increased work of
breathing can be observed due to dysfunctional breathing
patterns with an increased respiratory rate, the need for the use
of accessory muscles, and dynamic hyperinflation.
• Cognitive-emotional: Misconceptions and paying too
much attention to the sensation of breathlessness such as
memories of past or negative experiences lead to anxiety, distress,
feelings of panic, and thoughts about dying.
• Physical: Persons suffering from severe breathlessness show
reduced physical activity with a tendency to self-isolation and the
need for more help from others. This leads to deconditioning of
limb, chest wall and accessory muscles.
We expect a huge number of studies and categories of interven-
tions to be included. Therefore, three different reviews, based on
the theoretical concept, will be conducted. An additional review
is planned, focusing on interventions targeting more than one un-
derlying mechanism as described above.
In this review, we will analyse non-pharmacological interventions
targeting primarily cognition and/or emotion to relieve breath-
lessness in patients suffering from advanced stages of disease, for
example distractive auditory stimuli (music), meditation/relax-
ation (e.g. visual or guided imagery; progressivemuscle relaxation),
biofeedback, mindfulness-based stress reduction, and psycholog-
ical therapy (e.g. cognitive behavioural therapy). These interven-
tions may take place in a variety of settings, and can, with guid-
ance of healthcare professionals, mostly be carried out by patients
themselves (Figure 2).
Figure 2. System-based logic model on cognitive-emotional interventions for breathlessness in patients
with advanced diseases
Invasive interventions could also be classified as non-pharmaco-
logical but they will not be the focus in this review. Therefore,
we will exclude surgical procedures such as drainage, tapping, en-
doscopy, ventilation and catheterisation.
We will also exclude the following non-pharmacological interven-
tions as there have been recent Cochrane Reviews: pulmonary re-
habilitation (McCarthy 2015), and nutrition (Ferreira 2012).
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How the intervention might work
All interventions that will be subsumed in this review aim to ad-
dress andmodify behaviour, mood, emotional state and cognition.
This may help people suffering from advanced diseases to better
cope with their breathlessness. Cognitive-emotional interventions
target the training of coping strategies, the reduction of fear and
stress relating to breathlessness or the enhancement of positive
thinking. Different types of cognitive-emotional techniques are of
interest in this review.
Psychological therapy, for example cognitive behavioural ther-
apy, aims to help patients to break through the vicious cycle of
breathlessness and activity avoidance, by providing, among oth-
ers, behavioural activation, and problem-solving techniques (von
Leupoldt 2012).
Relaxation and meditative techniques aim to produce a stage of
relaxation and stress relief through elimination of environmental
distractions (Glanze 2012).
Distractive auditory stimuli (music) with and without exercise are
supposed to reduce the intensity of symptoms, e.g. breathlessness,
through drawing the attention away from the symptoms (Lee
2015).
Based on a template byRohwer 2017 we developed a system-based
logic model in which we show how non-pharmacological inter-
ventions for breathlessness, with a focus on interventions predom-
inantly targeting cognition and/or emotion, are implemented in
the healthcare system (Figure 2).
Why it is important to do this review
Non-pharmacological interventions can complement pharmaco-
logical interventions and may offer alternative treatment options
in themanagement of breathlessness occurring in advanced illness.
As research into this challenging, poorly managed and burden-
some symptom is rapidly evolving, there is a need to synthesise the
most recent evidence to inform practice and research. Our review
aim is to aid health professionals in the treatment of breathlessness
with palliative intent and to inform patients and carers about the
evidence of non-pharmacological interventions targeting cogni-
tion, emotion or both to relieve breathlessness.
This is an update of a Cochrane review on non-pharmacologi-
cal interventions for the relief of breathlessness in advanced dis-
ease (Bausewein 2008). The former review showed effectiveness of
neuromuscular electrical stimulation, chest wall vibration, walk-
ing aids, and breathing training. The review included 47 stud-
ies that were categorised in different intervention groups (e.g.
walking aids, acupuncture, breathing training, psychological ther-
apy). Since its publication,many randomised controlled studies on
non-pharmacological interventions have been published, includ-
ing new intervention groups (e.g. breathlessness services). There-
fore, although necessary, a single review as an update of the earlier
review seemed infeasible. Based on the interventions used to target
breathlessness, we decided to assess the interventions in different
reviews.
O B J E C T I V E S
To assess the effects and safety of interventions targeting cognition,
emotion or both as the predominant underlying mechanism of
effect to relieve breathlessness in adults suffering from advanced
diseases.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs), cluster
RCTs, and quasi-RCTs (QRCTs). Quasi-randomisation is defined
as some pseudo-random method of allocation such as alternation,
date of birth, case record number or date of presentation (Higgins
2011). We will include cross-over studies, if separate data for both
time periods are presented. We will only use the data of the first
period for analysis to avoid carry-over effects. We will require full
journal publication. Where full journal publication is not avail-
able, we will try to obtain data by contacting the trial authors
unless sufficient data for analyses are provided in online clinical
trial results, summaries of otherwise unpublished clinical trials, or
conference abstracts. QRCTs will be included in order to obtain
the full breadth of relevant trials, in particular as we expect to find
a small number of RCTs for some of the intervention categories;
we are aware of the higher risk of bias in these studies and will
account for this in the analysis.
Types of participants
Adult patients aged 18 years and above, suffering from advanced
diseases with a high prevalence of breathlessness.
We will include studies if the majority (≥ 50%) of participants
meet the following criteria.
• Patients suffering from cancer should have advanced local
or metastatic disease (e.g. TNM Classification of Malignant
Tumours (TNM) state ≥ T3 or N ≥ 1 or M ≥ 1).
• Patients with severe COPD should have a forced expiratory
volume in one second (FEV1) predicted of < 50%.
• Patients with pulmonary hypertension will be included if
they reach a WHO class level ≥ III, defined by Barst 2004.
• Patients suffering from CHF should have New York Heart
Association (NYHA) stage III or IV.
• Patients with ILD or idiopathic pulmonary fibrosis (IPF) :
all studies will be included as breathlessness is the predominant
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symptom and there are hardly any disease-specific treatment
options.
• Patients with neuromuscular diseases (MND, ALS): all
studies will be included as advanced disease is marked by the
occurrence of breathlessness.
If groups for the inclusion criteriamentioned above were stratified,
we will only include the subgroups of interest. We will document
difficult decisions in the review. Sensitivity analysis can assess the
impact of these decisions on the review’s result. Patients included
in the studies can be in any setting. We will exclude studies of
patients with any condition not regarded as advanced and life-
limiting such as acute or chronic asthma, or with pre-existing
diagnosis of acute asthma or acute cardiac condition as a primary
cause of breathlessness.
Types of interventions
Wewill include interventions targeting cognition, emotionor both
to relieve breathlessness according to the following prespecified
categories.
• Distractive auditory stimuli (music).
• Meditation/relaxation (e.g. visual/guided imagery;
progressive muscle relaxation).
• Biofeedback.
• Mindfulness-based stress reduction.
• Psychological therapy (e.g. cognitive behavioural therapy).
If we find interventions of interest that do not fit in the above
categories, we will define an additional category ’Other’ or add
new categories if there is a sufficient number of studies.
The judgement for inclusion will be based on the study authors’
description of the intervention; any deviation from this will be
explicitly mentioned.
Interventions may take place in any setting, e.g. outpatient clinic,
home, hospital, hospice, general medical practice.
The comparator may be no treatment, placebo, attention control,
standard care, or a different kind of therapy. We will categorise
the control groups into ’active controls’ or ’other’ based on the
description of the comparison group. We will focus on active con-
trols as comparison group in our primary analysis. Concomitant
interventions, especially pharmacological treatment, will be ac-
cepted, if administered in the same way in both the control and
the treatment groups. If these interventions are suspected to have
some relevant influence on our outcomes we will consider this in
subgroup analysis.
Types of outcome measures
We anticipate that studies will use a variety of outcome measures.
To be included, a study must have any measure of breathlessness.
Adverse effects of cognitive-emotional interventions will be mea-
sured as absent or present and a narrative description of these ef-
fects will be given when reported. We will consider all reliable and
validated measures for the following outcomes.
Primary outcomes
Breathlessness, measured by self-reported instruments with a focus
on breathlessness or mastery of breathlessness (e.g. Baseline Dysp-
noea Index (BDI), Borg Dyspnoea Scale (BDS), Medical Research
Council (MRC) Breathlessness Scale, or Chronic Respiratory Dis-
ease Questionnaire (CRQ)). Other terms for breathlessness such
as dyspnoea, shortness of breath, and difficulty breathing will also
be accepted.
Secondary outcomes
• Performance parameters (e.g. walking tests, International
Physical Activity Questionnaire (IPAQ)).
• Respiratory parameters (e.g. change in FEV1(%)).
• Change in depression, anxiety and/or distress (e.g. Hospital
Anxiety and Depression Scale (HADS)).
• Quality of life (e.g. 36-Item Short Form Health Survey (SF-
36)).
• Safety outcomes:
◦ Adverse events (measured as absent or present);
◦ Dropout rates; and
◦ Patient withdrawal from the trial, due to any reason (if
mentioned).
Search methods for identification of studies
Electronic searches
We will search the following databases from their inception to the
present, without date or language restrictions.
• Cochrane Database of Systematic Reviews (CDSR), the
Cochrane Library.
• Cochrane Central Register of Controlled Trials
(CENTRAL), the Cochrane Library.
• MEDLINE (Ovid).
• Embase (Ovid).
• PsycINFO (Ovid).
• LILACS (Bireme)
• CINAHL (Ebsco).
We will search MEDLINE and Embase using both controlled vo-
cabulary (namely, MeSH in MEDLINE and EMTREE in Em-
base) and a wide range of free-text terms. To detect all RCTs we
will perform the search onMEDLINE using theCochrane Highly
Sensitive Search Strategy, sensitivity-maximising version (Higgins
2011).
The search strategy for MEDLINE is in Appendix 1.
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Searching other resources
We will search the meta-register of controlled tri-
als (mRCT) (www.controlled-trials.com/mrct), clinicaltrials.gov (
www.clinicaltrials.gov) and the WHO International Clinical Tri-
als Registry Platform (ICTRP) (apps.who.int/trialsearch/) for on-
going trials. In addition, we will check reference lists of reviews
and retrieved articles for additional studies, and we will perform
citation searches on key articles. We will contact experts in the
field for unpublished and ongoing trials. We will contact study
authors where necessary for additional information.
We will perform the search in collaboration with the Information
Specialist of the Cochrane Pain, Palliative and Supportive Care
Group.
Data collection and analysis
Selection of studies
Two review authors (AB, SR) will independently screen all titles
and abstracts retrieved by the search to identify all trials that may
be eligible and for which the full paper should be obtained. Inde-
pendent review authors will eliminate studies that clearly do not
satisfy inclusion criteria, and obtain full copies of the remaining
studies. Two review authors (AB, SR) will read these studies inde-
pendently to select relevant studies, and in the event of disagree-
ment or unclear decision to include, we will resolve disagreement
with a third author (MM or CB, depending on the topic). We will
not anonymise the studies in any way before assessment.
We will include a PRISMA flow chart in the full review which
will show the status of identified studies (Moher 2009) as recom-
mended in Part 2, Section 11.2.1 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).We will include
studies in the review irrespective of whether measured outcome
data are reported in a ‘usable’ way.
Data extraction and management
Two review authors (SR, AB, AH or MM) will independently
extract data using a data collection form based on a standard form
released by the Cochrane Effective Practice and Organisation of
Care Group (EPOC) and check for agreement before entry into
Review Manager (RevMan 2014). Where there is disagreement, a
third author (CB or SB) will be consulted to resolve differences.
We will include information about the following.
Participant characteristics
• Demographic characteristics (age, gender, nationality).
• Underlying disease characteristics (type and stage of
condition).
Intervention
• Intervention theory
• Type of intervention (description of intervention,
frequency, duration (total and per session)).
• Types of control condition (control intervention, control
group).
• Type of delivery (delivery mechanisms such as face-to-face,
distant; group, individual; provider characteristics such as nurses,
physicians, multiprofessional; setting such as outpatient clinic,
home, hospital).
Methods
• Study design.
• Size of intervention and control group at baseline and
follow-up.
• Study duration and follow-up.
• Sources of bias (sequence generation, allocation sequence
concealment, blinding, incomplete outcome data, selective
reporting, other concerns about bias).
Outcomes
• Key outcomes with measurement instruments.
• Timing, duration and frequency of follow-up.
• Adverse events.
• Number of withdrawals and dropouts.
Context
• Country of origin.
In casemultiple reports of the same study are found, wewill extract
data of all these reports independently of each other and compare;
if data differ between reports, all authors will make a decision how
to treat this study and this will be documented in the review. We
will collate multiple reports of the same study, so that each study
rather than each report is the unit of interest in the review. We will
collect characteristics of the included studies in sufficient detail to
populate a table of ‘Characteristics of included studies’ in the full
review. Review authors will not be involved in the data extraction
of studies they authored or co-authored.
Assessment of risk of bias in included studies
Two authors (AB, AH) will independently assess risk of bias for
each study, using the criteria outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) and
adapted from those used by the Cochrane Pregnancy and Child-
birth Group.
We will assess the following for each study.
• Random sequence generation (checking for possible
selection bias). We will assess the method used to generate the
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allocation sequence as: low risk of bias (any truly random
process, e.g. random number table; computer random number
generator); unclear risk of bias (method used to generate
sequence not clearly stated). Studies using a non-random process
(e.g. odd or even date of birth; hospital or clinic record number)
will be assessed as high risk of bias.
• Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during, recruitment,
or changed after assignment. We will assess the methods as: low
risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes); high risk of
bias (studies that do not conceal allocation (e.g. open list);
unclear risk of bias (method not clearly stated).
• Blinding of outcome assessment (checking for possible
detection bias). We will assess the methods used to blind study
participants and outcome assessors from knowledge of which
intervention a participant received. We will assess the methods
as: low risk of bias (study states that it was blinded and describes
the method used to achieve blinding); high risk of bias (no or
incomplete blinding); unclear risk of bias (study states that it was
blinded but does not provide an adequate description of how it
was achieved). We will also report if study participants are asked
about their expectations of benefit of intervention/control if
blinding is not feasible.
• Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data). We will assess the methods used to deal with
incomplete data as: low risk (< 10% of participants did not
complete the study and/or data have been imputed using
appropriate methods); high risk of bias (used ’completer’
analysis); unclear risk of bias (insufficient information for low/
high risk of bias category).
• Selective reporting (checking for reporting bias). We will
assess the methods as: low risk of bias (where it is clear that all of
the study’s prespecified outcomes and all expected outcomes of
interest to the review have been reported); high risk of bias
(where not all the study’s prespecified outcomes have been
reported; one or more reported primary outcomes were not
prespecified; outcomes of interest are reported incompletely and
so cannot be used; study fails to include results of a key outcome
that would have been expected to have been reported); unclear
risk of bias (insufficient information for low/high risk of bias
category).
• Other bias (e.g. checking for possible biases confounded by
small size. We will assess studies as being at low risk of bias (≥
200 participants per treatment arm); unclear risk of bias (50 to
199 participants per treatment arm); high risk of bias (< 50
participants per treatment arm)).
We will use the Review Manager tool to complete a ’Risk of bias’
table (RevMan 2014). Any discrepancy between the two authors
will be resolved by discussion involving a third author (CB).
Measures of treatment effect
We will analyse dichotomous outcomes using risk ratios (RRs)
with 95% confidence intervals (CIs). We will recategorise any cat-
egorical outcomes with more than two categories into two groups.
We will analyse continuous data using standardised mean differ-
ences (SMDs) with 95% CIs. We will calculate standard devia-
tions, if not reported, using themethods described in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We plan to report the proportion of participants experiencing any
adverse effects of cognitive-emotional interventions, and combine
studies using RRs with 95% CIs.
Unit of analysis issues
We will reanalyse data, if possible, for cluster trials which have not
taken clustering into account in their analysis. We will calculate
effective sample sizes and adjusted standard errors using the de-
sign effect method. We will try to obtain estimates for intraclus-
ter correlation coefficients from study authors or will use external
estimates obtained from comparable studies, as recommended by
Cochrane guidelines (Higgins 2011). We will document if reanal-
ysis is not feasible.
In studies with more than two arms, we will consistently choose
the active control arms in the main analysis, and, if possible, do
a sensitivity analysis, in which we will choose the other control
arm. We will combine individually randomised controlled trials
and cluster RCTs in the same meta-analyses or harvest plots, but
these will be clearly identified (Higgins 2011).
Dealing with missing data
We will contact study authors if missing data on study charac-
teristics or outcome measures precludes study inclusion or limits
use of a study at further stages of the review. If studies do not
report outcomes based on intention-to-treat analyses this will be
considered as a source of bias during ’Risk of bias’ assessment. We
will try to calculate effect measures or CIs wherever possible from
available data, if we get no response.
Assessment of heterogeneity
We will assess methodological and clinical heterogeneity with ta-
bles documenting the following characteristics of the included
studies.
• Intervention components (e.g. music, meditation/
relaxation, biofeedback, psychological therapy).
• Intervention delivery mechanism (e.g. face-to-face, distant).
• Provider characteristics (e.g. nurses, physiotherapists,
physicians).
• Setting (e.g. outpatient clinic, hospice, home).
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• Patients (e.g. COPD, cancer, fibrosing lung disease).
• Methods (outcome measures, outcome assessment).
For those studies assessing the impacts of a given intervention
category on comparable outcomes, thus making pooling through
meta-analysis feasible, wewill assess statistical heterogeneity graph-
ically with a forest plot by examining the extent to which CIs over-
lap, and statistically with the I2 statistic. We will consider an I2
value greater than 50% to indicate substantial statistical hetero-
geneity, and will consider it statistically significant if the P value for
the Chi2 test is < 0.1. We will document statistical heterogeneity
but this will not have any direct consequences for meta-analysis
(see below). We will create forest plots and I2 calculations using
Review Manager 5.3 (RevMan 2014).
Assessment of reporting biases
Wewill try tominimise publicationbias by searching trials registers
for projected and registered studies that have never been published.
We will contact the authors to get unpublished information if
there are such studies registered or some relevant information is
missing and can therefore narrow the risk of reporting bias. We
will assess the possibility that publication bias affects the review
using funnel plots when at least 10 studies are available for meta-
analysis.
Data synthesis
We will attempt to pool all studies within a given intervention
category assessing the same outcome by conducting a meta-anal-
ysis using Review Manager 5.3 (RevMan 2014). We will use the
random-effects model due to the expected large heterogeneity in
delivery mechanisms, provider characteristics, setting and study
population.
We will report results as RRs for dichotomous outcomes and
SMDs for continuous outcomes. We will undertake meta-analysis
only if studies are judged to be similar enough to give a clinically
meaningful answer. We will provide an outcome table and sum-
marise the results narratively if meta-analysis is not possible.
In the case of skewed data, we will log transform these data for
our analysis or, if that approach is not feasible, summarise them
narratively.
’Summary of findings’ table
We will include a ’Summary of findings’ table using the GRADE
profiler software (GRADEpro GDT 2015) as set out in the PaPaS
author guide (AUREF 2012) and recommended in the Cochrane
Handbook for Systematic Reviews of Interventions, Chapter 4.6.6
(Higgins 2011) to evaluate the quality of evidence in our review.
The ’Summary of findings’ table will include outcomes of: a)
change of breathlessness, b) objective parameters of breathlessness,
c) quality of life indicators, d) change of depression or anxiety,
e) adverse events, f ) characteristics of the patient population that
benefits most.
Quality of the evidence
This section is taken from theCochraneDrugs andAlcoholGroup
recommended text. The overall quality of the evidence for each
outcome in our review will be assessed using the GRADE system
(GRADEpro GDT 2015) and presented in the ’Summary of find-
ings’ tables, to present the main findings of a review in a transpar-
ent and simple tabular format. In particular, we will include key
information concerning the quality of evidence, the magnitude of
effect of the interventions examined, and the sum of available data
on the main outcomes.
The GRADE system uses the following criteria for assigning grade
of evidence.
• High: we are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of
effect, but there is a possibility that it is substantially different.
• Low: our confidence in the effect estimate is limited; the
true effect may be substantially different from the estimate of the
effect.
• Very low: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
Wewill decrease grade rating by one (- 1) or two (- 2) if we identify:
• serious (-1) or very serious (-2) limitation to study quality;
• important inconsistency (-1);
• some (-1) or major (-2) uncertainty about directness;
• imprecise or sparse data (-1); or
• high probability of reporting bias (-1).
Subgroup analysis and investigation of heterogeneity
We will undertake subgroup analysis for the primary outcomes
to examine factors that may explain variation in the effectiveness,
if numbers are sufficiently large. We will perform stratification as
follows.
• Type of intervention.
• Intervention delivery (delivery mechanisms such as face-to-
face, distant; group, individual; provider characteristics such as
nurses, physicians, multiprofessional; setting such as outpatient
clinic, home, hospital).
• Patient characteristics (underlying disease, disease stage,
age, gender).
• Underlying therapy
Sensitivity analysis
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We will conduct sensitivity analysis where possible, to test the
effect of different methodological decisions made throughout the
review process on the primary outcome.Wewill test the robustness
of the results by removing from the pooled effect estimate:
• studies with a high risk of bias for two or more key domains;
• quasi-randomised clinical trials;
• outcome measures; and
• intervention of varying duration.
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A P P E N D I C E S
Appendix 1. Search strategy for MEDLINE (Ovid)
1. exp Dyspnea/
2. dyspn?ea.tw.
3. (short* adj2 breath).tw.
4. (urge* adj2 breath*).tw.
5. breathless*.tw.
6. ((labo?red or difficult* or small) adj3 breath*).tw.
7. ((respirat* or breath*) adj3 (distress* or comfort* or discomfort*)).tw.
8. (air adj3 (hunger or starve* or need* or gasp* or pant*)).tw.
9. suffocat*.tw.
10. unsatisf* inspiration.tw.
11. or/1-10
12. Neoplasms/ or Lung Neoplasms/
13. ((lung* or bronchi* or pulmo*) adj3 (neoplasm* or cancer* or tumo?r* or metasta* or malignan*)).mp.
14. Lung diseases/
15. exp Pulmonary Disease, Chronic Obstructive/
16. (COPD or COAD).tw.
17. Lung Diseases, Obstructive/
18. (obstruct* adj3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)).tw.
19. hypertension, pulmonary/
20. or/12-19
21. exp Heart Failure/
22. ((heart or cardia* or myocard*) adj2 (fail* or insufficienc*)).tw.
23. (decompensat* adj2 (heart* or cardia*)).tw.
24. decompensatio cordis.tw.
25. insufficientia cardis.tw.
26. ((cardiac or heart) adj2 incompetenc*).tw.
27. cardiac stand still.tw.
28. or/21-27
29. exp Lung Diseases, Interstitial/
30. (interstitial adj3 (disease* or pneumoni* or fibrosis)).tw.
31. pulmonary fibrosis.tw.
32. fibrosing alveolitis.tw.
33. Cystic Fibrosis/
34. (cystic fibrosis or mucoviscidosis).tw.
35. or/29-34
36. exp Motor Neuron Disease/
37. (MND or ALS).tw.
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38. motor neuron disease*.tw.
39. sclerosis.tw.
40. Amyotrophic Lateral Sclerosis/
41. charcot disease*.tw.
42. lou gehrig disease*.tw.
43. encephalomyelitis disseminate.mp.
44. or/36-43
45. 20 or 28 or 35 or 44
46. ((end stage or advanc* or final or terminal* or limit*) adj3 (disease* or illness*)).tw.
47. Terminally Ill/
48. Terminal Care/
49. Palliative Care/
50. Prognosis/
51. ((advanc* or terminal or limit*) adj3 (prognos* or prospect* or prediction*)).tw.
52. disease progression/
53. ((incurable or worsen* or chronic) adj3 (illness* or disease*)).tw.
54. or/46-53
55. 45 or 54
56. randomized controlled trial.pt.
57. controlled clinical trial.pt.
58. randomized.ab.
59. placebo.ab.
60. drug therapy.fs.
61. randomly.ab.
62. trial.ab.
63. groups.ab.
64. 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63
65. exp animals/ not humans.sh.
66. 64 not 65
67. 11 and 55
68. 66 and 67
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